| 摘要 |
Disclosed herein is tha use of a topical preparation of a DPP-4 inhibitor which is 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(R)-amino-piperidin-1-yl)-xanthine with suitable carrier materials selected from glycerides, semi-synthetic and synthetic glycerides, hydrogenated oils, liquid waxes, liquid paraffins, liquid fatty alcohols, sterols, polyethylene glycols and/or cellulose derivatives, for treating a type 2 diabetes patient wherein the DPP-4 inhibitor exerts direct favourable (e.g. extraglycemic) effects on the wound repairing process in a type 2 diabetic subject. |
